<DOC>
	<DOCNO>NCT00124540</DOCNO>
	<brief_summary>This hospital-based , multicenter , randomize , placebo-controlled trial ass effect misoprostol part active management third stage labor postpartum blood loss , complication , side effect . Twelve hundred eligible woman receive routine oxytocic ( oxytocin 5-10 IU ) plus either 400 mcg sublingual misoprostol placebo immediately delivery . The primary outcome measure blood loss = &gt; 500 ml within one hour enrollment .</brief_summary>
	<brief_title>Misoprostol Preventing Postpartum Hemorrhage</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Postpartum Hemorrhage</mesh_term>
	<mesh_term>Misoprostol</mesh_term>
	<criteria>Women give birth 1 liveborn infant ( para 1 ) Vaginal delivery Refusal inability give inform consent Delivery regard abortion accord local gestational age limit Inability take misoprostol sublingually Cesarean section Assisted vaginal delivery</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Misoprostol</keyword>
	<keyword>Active management</keyword>
	<keyword>Postpartum hemorrhage</keyword>
	<keyword>Maternal morbidity</keyword>
	<keyword>Anemia</keyword>
	<keyword>Developing country</keyword>
</DOC>